Botanical and Plant-derived Drugs: Global Markets

Report Scope:

This report is an analytical business tool whose primary purpose is to describe the botanical drug industry with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.

For the purposes of this report, botanicals are those drugs that are FDA-approved under the botanical drug pathway, while plant-derived drugs are both botanicals as well as other approved drugs that contain a mixture of natural plant-derived and synthetic or semisynthetic substances.

The study’s main focus is on legal, prescription-required therapeutic medicines sold in the open market. The study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness†rather than to address a specific medical condition or symptoms). While there is a substantial market for these products, the medical value of many of these substances has not been demonstrated conclusively.

The study also does not cover the following:
- Underground or illicit drugs.
- Home remedies.
- Tribal medicines.
- Drugs derived from Archaea, bacteria and fungi (molds and yeasts).
- Nonmedicinal plant substances, such as laxative cellulose and pectin fiber.
- Intravenously delivered nutrients of plant origin, such as dextrose.
- Plant-derived substances serving as pharmaceutical excipients, such as starch, methylcellulose, guar gum, vegetable oils, fatty acids, cocoa butter and candelilla wax.
- Plant substances serving in cosmetics, toiletries and personal care products.
- Microbial fermentation products, even those made with culture media incorporating corn steep liquor, starch or other plant-derived nutrients.
- Marine life.

The format of the study is organized around the following topics:
- Major types and applications of botanical drugs with plant-derived drugs as their backdrop.
- Industry structure.
- Market size and segmentation, including the breakdown of sales by therapeutic area and geographic area.
- Market drivers.
- Market projections through 2022.
- Competition.
- Observations and conclusions regarding the future of the botanical and plant-derived drug industry.

Report Includes:

- An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward
- Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
- A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness†rather than to address specific medical conditions or symptoms)
- Examination of the industry structure, competition, and market drivers
- Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area
- Observations and conclusions regarding the future of the botanical and plant-derived drug industry.


Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analysts Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Trends and Drivers for Botanical Drug Development
Chapter 3 Market and Technology Background
Brief History of Plant-Derived Medicines
Opportunity Lies Beyond What Is Known
Getting Started
Key Drivers
Key Challenges
U.S. Government Investment
Industry Investment
Nutrition Science Partners Ltd. (Nestlé Health): A Case Study
Botanical Drugs Defined
Understanding the Regulatory Process
Investigational New Drug Applications
Clinical Trials
New Drug Application
The First and Second U.S. Approved Botanical Drug
Veregen (Chinese Green Tea Catechins)
Mytesi, Formerly Fulyzaq (Crofelemer)
Botanical Candidates in the Pipeline
Samital
Danshen Dripping Pill (Cardiotonic Pill)
EISO (East Indian Sandalwood Oil)
Microbio and WH-1, MB-6 and OB318
A Growing Pipeline
Overall Pharma Landscape
Major Classes of Plant Drugs
Terpenes and Steroids
Alkaloids and Glycosides
Phenols
Proanthocyanidins
The Emergence of Cannabinoids
Intellectual Property
Production
A New Type of Production: Plant-Made Drugs
Moving Production Forward
Supply and Legal Issues
Drug Development and Manufacture
Chapter 4 Market Breakdown by Technology Type
Sales of Plant-derived Drugs by Region
Plant-derived Drugs by Therapeutic Area
Value of Plant-derived Drugs by Therapeutic Area
A Pipeline Perspective: Composition of Botanical Drugs in Clinical Development
Chapter 5 New Developments and Market Opportunities
Hormone Therapy and Metabolism Applications
Infectious Disease Applications
Pain and Central Nervous System Disease Applications
Cardiovascular and Metabolic Applications
Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Applications
Dermatology Applications
Gastrointestinal Applications
Oncology Applications
Botanical Drugs in Clinical Development
Promising Candidates for Botanical Drugs
Chapter 6 Company Profiles
ABBOTT LABORATORIES
ACORDA THERAPEUTICS INC.
AMAREX CLINICAL RESEARCH
ANALYTICON DISCOVERY GMBH
ARTECEF BV
BAYER HEALTHCARE PHARMACEUTICALS
BIONORICA SE
BIONUMERIK PHARMACEUTICALS INC.
BOEHRINGER INGELHEIM
Pharmaton SA
BRISTOL-MYERS SQUIBB
CARDAX PHARMACEUTICALS
CHI-MED
CHONG KUN DANG PHARMACEUTICAL CORP.
CHUNG MEI BIOPHARMA CO LTD
CURAPHARM INC.
DONG-A-ST
DONGWHA PHARM CO. LTD.
EISAI INC.
EISAI Inc. U.S.
EKOMED LLC
ELI LILLY
FYTOKEM PRODUCTS INC.
GALAPAGOS NV
GLAXOSMITHKLINE
GLENMARK PHARMACEUTICALS LIMITED
GREEN CROSS CORP.
GREEN LABORATORIES LLC
GW PHARMACEUTICALS PLC
HAMIDA PHARMA INC.
HANMI PHARMA CO. LTD.
HETEROGENEITY LLC
HSRX BIOPHARMACEUTICAL
INDENA
INDUS BIOTECH
INMED PHARMACEUTICALS
INSPYR THERAPEUTICS INC.
INSYS THERAPEUTICS INC
IZUN PHARMACEUTICALS CORP.
JOHNSON & JOHNSON
KANGLAITE USA INC.
LANZHOU FOCI PHARMACEUTICALS CO. LTD.
LEO PHARMA
LUPIN PHARMACEUTICALS INC.
MEDIGENE AG
MERCK & CO. INC.
MERLION PHARMACEUTICALS
MICROBIO CO. LTD.
MYCOSYNTHETIX INC.
NAPO PHARMACEUTICALS INC.
NOVARTIS INTERNATIONAL AG
PFIZER
PHARMACEUTICAL PLANT CO.
PHYNOVA
PHYTOMYCO RESEARCH PVT. LTD.
PHYTOPHARMACON INC.
PHYTOQUEST LTD
PIRAMAL PHYTOCARE LTD.
PRAIRIE PLANT SYSTEMS INC.
PRANA THERAPEUTICS
PUNISYN PHARMACEUTICALS LTD. (RIMONEST LTD.)
PURAPHARM INTERNATIONAL LTD.
QUERCEGEN PHARMACEUTICALS LLC
ROTTAPHARM (MADAUS)
SANOFI
SANTALIS PHARMACEUTICALS
Quintis Ltd. (PARENT COMPANY)
SCHWABE PHARMACEUTICALS
SE-CURE PHARMACEUTICALS LTD.
SEQUOIA SCIENCES INC.
SUN PHARMACEUTICAL INDUSTRIES LTD.
SUN TEN PHARMACEUTICAL CO. LTD.
TASLY PHARMACEUTICALS INC.
U.S. Location
TCM BIOTECH INTERNATIONAL CORP.
UNITED CANNABIS CORP.
VALEANT PHARMACEUTICALS INTERNATIONAL INC. (SALIX PHARMACEUTICALS INC.)
Salix Pharmaceuticals
VEDIC LIFESCIENCES PVT. LTD.
YIVIVA
Chapter 7 Appendix


List Of Tables


Summary Table : Global Market for Botanical and Plant-derived Drugs*, by Type, Through 2022
Table 1 : Key Events Related to Botanical Medicine
Table 2 : Notable Plant-derived Drugs
Table 3 : Number of Botanicals Pre-INDS and INDs Submitted to the FDA, by Type, Through 2013
Table 4 : SWOT Analysis of Botanical Drug Development
Table 5 : Key Investments in Botanical and Other Plant-derived Drugs
Table 6 : Distinctions Among Products That Use Plants Medicinally
Table 7 : Botanical Composition of Menerba (MF 101)*
Table 8 : Top Pharma Companies, by Revenue, 2016
Table 9 : Major Upcoming U.S. Patent Expiries, 2014-2022
Table 10 : Major Producers of Raw Materials for Plant-Based Medicine
Table 11 : Key Companies with Natural Product Libraries
Table 12 : Number of FDA-Approved Botanical Drugs, Through 2022
Table 13 : Global FDA-Approved Botanical Drugs Market, by Therapeutic Area, Through 2022
Table 14 : Plant-derived Hormone Therapy and Metabolism Drugs in Late-Stage Development
Table 15 : Plant-derived Infectious Disease Drugs in Late-Stage Development
Table 16 : Brain Disorders That are Refractory to Small Molecule Drugs
Table 17 : Plant-derived Pain and CNS Drugs in Late-Stage Development
Table 18 : Plant-derived Cardiovascular and Metabolic Drugs in Late-Stage Development
Table 19 : Plant-Derived Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Drugs in Late-Stage Development
Table 20 : Plant-derived Dermatology/Wound Care Drugs in Late-Stage Development
Table 21 : Plant-derived Gastrointestinal Drugs in Late-Stage Development
Table 22 : Estimated U.S. New Cancer Cases, by Gender, 2016
Table 23 : Plant-derived Oncology Drugs in Late-Stage Development
Table 24 : Botanical Drugs in Clinical Development with Possible FDA-Approved Commercialization, Through 2022
Table 25 : Promising Compounds Being Studied for Medicinal/Therapeutic Potential
Table 26 : Plant-derived Drugs: Their Origin and Actions
Table 27 : Useful Resources for the Botanical Industry


List Of Figures


Summary Figure : Global Market for Botanical and Plant-derived Drugs*, by Type, 2016-2022
Figure 1 : Top Therapeutic Areas of FDA Drug Approvals, 2016
Figure 2 : Composition of FDA-Approved Botanical Indications, by Therapeutic Area, 2017 and 2022
Figure 3 : Global FDA-Approved Botanical Drugs Market, by Therapeutic Area, 2017 and 2022
Figure 4 : Therapeutic Areas Targeted for Botanical Drugs in Phase 2 or Later, 2017*


COVID-19 Outbreak-Global Botanical And Plant-Derived Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

The Botanical And Plant-Derived Drugs market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.Under COVID-19 outbreak

USD 3660 View Report

Asia Pacific Botanical And Plant Derived Drugs Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Asia Pacific Botanical and Plant Derived Drugs market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX

USD 3000 View Report

COVID-19 Outbreak-Global Botanical And Plant-Derived Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020

The Botanical And Plant-Derived Drugs market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.Under COVID-19 outbreak

USD 3660 View Report

Asia Pacific Botanical And Plant Derived Drugs Market Report (2014-2024) - Market Size, Share, Price, Trend and Forecast

Abstract:The Asia Pacific Botanical and Plant Derived Drugs market size is $XX million USD in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX

USD 3000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available